Human Breast Cell MDA-MB-231 based Proliferation Assay Service
Creative Biolabs delivers specific, high-resolution data essential for de-risking your oncology pipeline against the aggressive phenotype of triple-negative breast cancer (TNBC). Our service goes beyond generic viability testing to provide precise measurements of growth inhibition. This is coupled with critical mechanistic insights specifically tailored for this highly metastatic cell line, ensuring your drug candidates are validated against one of the most challenging cancer types. We offer the precision needed to understand and overcome TNBC's unique resistance and metastatic drivers.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The MDA-MB-231 Model and Mechanistic Relevance
The MDA-MB-231 cell line serves as the industry's gold standard for modeling aggressive, highly metastatic TNBC. Its utility is grounded in its capacity to represent the clinical phenotype of TNBC, characterized by high invasiveness and epithelial-to-mesenchymal transition (EMT). Recent scientific literature underscores that effective therapies must not only inhibit cell growth but also disrupt key molecular drivers, such as the induction of apoptosis and the modulation of regulatory ncRNAs. For example, evidence shows that anti-cancer agents can exert their effects by upregulating the tumor-suppressive expression, thereby repressing oncogenic targets that drive proliferation.
Key Deliverables and Solutions for De-Risking Your Pipeline
Accurate IC50 and EC50 Determination
Using highly sensitive luminescent readouts and kinetic analysis to rapidly triage large compound libraries and identify potent hits.
Context-Dependent Efficacy Data
Testing your compounds in varying microenvironmental conditions to generate predictive data that reflects the complexity of the tumor microenvironment (TME).
Mechanistic Validation Support
Offering immediate follow-up assays to confirm the mode of action, such as verifying the induction of apoptosis or identifying molecular targets.
Beyond preclinical promise? Partner with us to translate your next-generation TNBC therapy into confirmed clinical efficacy.
Workflow: A Transparent Path to Efficacy Data
We have designed a robust, transparent, and multi-stage process to ensure maximum project clarity and data integrity for our clients, optimized for visualization as a clear flowchart.
Publication
This study finds that alisol A, a natural triterpenoid, has anti-cancer potential in TNBC MDA-MB-231 cells. It suppresses proliferation, migration, and invasion. Mechanistically, alisol A induces autophagy (increased LC3-II levels) by suppressing the PI3K/Akt/mTOR and NF-κB pathways. It also induces G0/G1 cell cycle arrest and exhibits anti-metastatic activity by inhibiting MMP-2/MMP-9, making it a promising therapeutic candidate.
Fig.1 Alisol A induces apoptosis in MDA-MB-231 cells. 1
Why Choose Us
Choosing Creative Biolabs means partnering with experts who fully grasp the molecular aggression of TNBC and the critical limitations of conventional in vitro screening. Our unique advantages ensure your data is accurate, reproducible, and highly relevant to clinical outcomes.
Unmatched Expertise in Metastatic TNBC Modeling
We provide access to dedicated scientists specializing in metastatic cell lines like MDA-MB-231 and the development of complex TME models, ensuring maximum clinical relevance.
Superior Clinically Predictive Data
We prioritize context-dependent phenotype profiling, proactively testing variables like serum concentration to avoid false positives and mitigate risks associated with simple in vitro IC50 data.
Integrated Mechanistic Assessment
Our service includes immediate, high-resolution molecular follow-up to confirm specific molecular targets, such as the regulation of the PI3K/Akt/mTOR axis or apoptosis activation, accelerating target validation.
Guaranteed Quality and Compliance
All assays adhere to certified quality management systems, ensuring accurate and reproducible data for regulatory submissions.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: How does the proliferation assay handle the challenge of drug resistance and TNBC heterogeneity?
A1: We address resistance by deliberately moving beyond simplistic 2D culture. Creative Biolabs routinely offers assays in complex microenvironments that better mimic the in vivo environment where resistance mechanisms often arise.
Q2: Why should I choose your IC50 assay over standard colorimetric kits I can run internally?
A2: Our service uses a cutting-edge luminescent detection system, which offers significantly superior sensitivity, a wider linear range, and reduced interference compared to traditional colorimetric methods.
Q3: My compound affects a specific molecular pathway. Can you confirm its mechanism beyond just cell counting?
A3: Absolutely. Our service is intentionally integrated with advanced mechanistic follow-up. We can perform high-resolution assays like Western Blot to confirm apoptosis pathway activation or qPCR to measure changes in key regulatory elements.
Customer Review
-
Reliable IC50 Data
Using Creative Biolabs' service in our research has significantly improved the confidence in our lead selection by revealing how serum content shifts the IC50 by over 40-fold, data crucial for predicting in vivo efficacy. - Dr. La*Hi
-
Physiological Relevance
Using Creative Biolabs' service in our research has significantly improved the physiological relevance of our screening by utilizing 3D spheroid models, which accurately captured resistance mechanisms not visible in standard 2D proliferation curves. - Dr. Krl*Mr
Related Services
To comprehensively validate your lead compound's activity against TNBC, Creative Biolabs offers several complementary services that build upon the foundational proliferation data:
Tumor Metabolic Pathway Analysis Services
Creative Biolabs offers comprehensive tumor metabolism pathway analysis services using multi-omic platforms. We investigate glucose, lipid, and amino acid metabolism to identify unique metabolic vulnerabilities and potential targets for cancer therapy.
Learn More →
Reaction Phenotyping Assessment Service
Creative Biolabs offers sensitive reaction phenotyping assays to identify the specific enzymes involved in drug metabolism using recombinant systems or human liver microsomes to predict drug-drug interactions.
Learn More →
Contact Us
Our comprehensive MDA-MB-231 based proliferation assay service, reinforced by advanced 3D modeling and integrated molecular profiling capabilities, provides the accurate, context-relevant data you need to drive successful research decisions against TNBC.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Lou, Chenghua, et al. "Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells." Molecules 24.20 (2019). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/molecules24203651
